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Background: Administration of exogenous progesterone for luteal phase support has become a standard of
practice. Intramuscular (IM) injections of progesterone in oil (PIO) and vaginal administration of progesterone are
the primary routes of administration. This report describes the administration preferences expressed by women
with infertility that were given progesterone vaginal insert (PVI) or progesterone in oil injections (PIO) for luteal
phase support during fresh IVF cycles.
Methods: A questionnaire to assess the tolerability, convenience, and ease of administration of PVI and PIO given
for luteal phase support was completed by infertile women diagnosed with PCOS and planning to undergo IVF.
The women participated in an open-label study of highly purified human menopausal gonadotropins (HP-hMG)
compared with recombinant FSH (rFSH) given for stimulation of ovulation.
Results: Most women commented on the convenience and ease of administration of PVI, while a majority of
women who administered IM PIO described experiencing pain. In addition, their partners often indicated that they
had experienced at least some anxiety regarding the administration of PIO. The most distinguishing difference
between PVI and PIO in this study was the overall patient preference for PVI. Despite the need to administer PVI
either twice a day or three times a day, 82.6% of the patients in the PVI group found it “very” or “somewhat
convenient” compared with 44.9% of women in the PIO group.
Conclusions: The results of this comprehensive, prospective patient survey, along with findings from other similar
reports, suggest that PVI provides an easy-to-use and convenient method for providing the necessary luteal phase
support for IVF cycles without the pain and inconvenience of daily IM PIO. Moreover, ongoing pregnancy rates with
the well-tolerated PVI were as good as the pregnancy rates with PIO.
Trial registration: ClinicalTrial.gov, NCT00805935
Keywords: Tolerability, Vaginal progesterone, Luteal support, Endometrium, IVF, Polycystic ovary syndrome* Correspondence: michael.collins@ferring.com
6Ferring Pharmaceuticals, Inc, 4 Gatehall Drive, Third Floor, Parsippany, NJ
07054, USA
Full list of author information is available at the end of the article
© 2014 Beltsos et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Beltsos et al. Reproductive Health 2014, 11:78 Page 2 of 7
http://www.reproductive-health-journal.com/content/11/1/78Background
Progesterone produced by the corpus luteum during the
luteal phase of the menstrual cycle promotes secretory
transformation of endometrial tissue, which is essential for
embryo implantation [1]. Use of gonadotropin-releasing
hormone (GnRH) agonists and antagonists administered
to patients during cycles of IVF may adversely affect luteal
function and compromise the production of progesterone
by the corpus luteum [1,2]. Administration of exogenous
progesterone for luteal phase support has become a stan-
dard of practice, and its administration has been shown to
improve pregnancy rates during cycles of IVF [3-5].
Progesterone is administered by oral, intramuscular (IM),
or vaginal routes [3-5]. However, because of poor bioavail-
ability of progesterone administered orally, IM injections of
progesterone in oil (PIO) and vaginal administration of pro-
gesterone are the primary routes used in clinical practice [6].
Administration of progesterone by IM and vaginal routes
appears to result in similar pregnancy rates [3,6-16]. Not-
ably, a recent retrospective study of a large cohort of women
undergoing IVF showed significantly better clinical preg-
nancy rates when progesterone was given by both
the IM and vaginal routes compared with the vaginal
route alone for IVF cycles with frozen embryo transfer
(P < 0.001); but no difference for IVF cycles with fresh au-
tologous (P= 0.05) or donor oocytes (P= 0.39) [17].
Surveys associated with clinical trials have shown that va-
ginal administration is preferred over IM administration by
most women [15,18,19]. Women prefer vaginal over IM ad-
ministration because vaginal administration is convenient,
easy to use, and does not involve the pain and side effects
commonly associated with daily IM injections [15,18,19].
This report describes the administration preferences
expressed by women with polycystic ovarian syndrome
(PCOS) who were given progesterone vaginal insert (PVI,
Endometrin®, Ferring Pharmaceuticals, Inc, Parsippany, NJ,
USA) or IM PIO (Progesterone Injection USP 50 mg/mL,
American Reagent, Corp, Shirley, NY, USA) for luteal phase
support during fresh IVF cycles.
Methods
Patients
To be eligible for this phase 4 study, participants had to be
premenopausal (women aged 18–42 years) with a
documented history of infertility (e.g., unable to conceive for
at least 1 year, or for 6 months for women aged 38 years or
older, or with bilateral tubal occlusion or absence of tubal
segments, or male factor) previously diagnosed with PCOS
and considered to be a favorable candidate to undergo an
assisted reproductive technology (ART) procedure. PCOS
was defined using the criteria adopted at the 2003 Rotter-
dam PCOS Consensus [20].
For study inclusion, women were required to have a body
mass index (BMI) of 18–39 kg/m2; an intact uterus adnexavisualized on transvaginal ultrasonography (TVU) per-
formed within 1 year of screening; and 2 of the following 3
conditions present: (1) oligo- or anovulation, (2) clinical
and/or biochemical signs of hyperandrogenism, and/or (3)
polycystic ovaries. Women were also required to have an
early follicular phase (day 3) serum follicle-stimulating
hormone (FSH) concentration ≤ 15 IU/L, and serum
estradiol (E2) concentration within normal limits for
4 months before screening.
Women were ineligible to participate if they had 2 or
more previous failed IVF cycles or poor response to go-
nadotropins (i.e., development of ≤ 2 mature follicles);
planned to use a gestational or surrogate carrier or donor
oocytes; had a history of recurrent pregnancy loss (>2);
currently had abnormal uterine bleeding of an undeter-
mined origin; or had a male partner with severe male factor
infertility who required invasive or surgical sperm retrieval
(e.g., microsurgical epididymal sperm aspiration, testicular
sperm extraction).
Women were also ineligible if they were diagnosed with
clinically relevant systemic disease (e.g., uncontrolled thyroid
and adrenal dysfunction, an organic intracranial lesion such
as a pituitary tumor, insulin-dependent diabetes mellitus,
uterine cancer); had a current or a recent history of
substance abuse, including alcohol abuse; smoked 10 or
more cigarettes per day; had a hypersensitivity to any of the
study drugs; or had any surgical or medical condition that,
in the investigator’s or sponsor’s judgment, would interfere
with absorption, distribution, metabolism, or excretion of
the study drugs.
The study was conducted in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki, followed the approved protocol, observed
International Conference on Harmonization–Good Clinical
Practice guidelines, and complied with all applicable re-
gulatory requirements. The protocol and its associated
Informed Consent Agreement were reviewed and approved
by the appropriate Institutional Review Board (Independent
Investigational Review Board, Inc., Women and Infants
Hospital of Rhode Island Institutional Review Board and
Weill Cornell Medical College Institutional Review Board).
Study personnel obtained written informed consent directly
from all participants before their entry into the study. This
trial is registered under NCT00805935 [https://clinicaltrials.
gov/].
Study design
This multicenter, randomized, open-label, phase 4, ex-
ploratory, study was conducted to assess the efficacy and
safety of highly purified human menopausal gonadotro-
pins (HP-hMG, Menopur® Ferring Pharmaceuticals, Inc,
Parsippany, NJ, USA) compared with recombinant FSH
(rFSH) during fresh cycles of IVF in otherwise healthy in-
fertile women who were diagnosed with PCOS and
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to PVI vs PIO. Women who participated in the study
completed a questionnaire to assess the tolerability, con-
venience, and ease of administration of PVI and PIO given
for luteal phase support.
Women were screened based on the study’s inclusion/
exclusion criteria, analysis of medical and infertility his-
tory, evaluation of FSH and E2 serum concentrations, re-
sults from physical and gynecological examinations, and
findings from the center’s standard screening evaluations
for IVF participants. TVU was performed and serum was
collected for E2 and progesterone concentration measure-
ment from all participants at baseline and periodically
throughout the study. All adverse events (AEs) and con-
comitant medications taken by participants were do-
cumented throughout the study. Patients returned to the
study center for regularly scheduled clinic visits as re-
quired per the IVF protocol and at other specified time
periods.
Study treatments
Leuprolide acetate, a GnRH agonist (GnRHa), was given
for pituitary downregulation. Participants were allowed
to use oral contraceptives before administration of the
GnRHa, if this was standard practice at the center.
Patients received daily injections of either HP-hMG
(Menopur®, Ferring Pharmaceuticals, Inc, Parsippany, NJ,
USA) 225 IU (3 vials) subcutaneously (SC) or follitropin
beta for injection (rFSH: Follistim®, Merck & Co Inc,
Whitehouse Station, NJ, USA) 225 IU SC for a minimum
of 5 days for ovarian stimulation. Human chorionic go-
nadotropin (hCG; Novarel®, Ferring Pharmaceuticals, Inc)
was administered to trigger ovulation.
Luteal phase support
Progesterone was administered to support the luteal
phase beginning on the day after oocyte retrieval. Pa-
tients were randomized to receive PVI 100 mg inserted
vaginally 2 or 3 times daily, or PIO 50-mg IM injection
once daily until 10-weeks’ gestation or confirmation of a
negative pregnancy test. A large, randomized control
trial previously demonstrated that there is no significant
difference in pregnancy outcomes between 2 and 3 times
daily dosing of PVI [21]. Each patient also took estradiol
tablets (Estrace®, Barr Laboratories, Inc, Pomona, NY,
USA) 2 mg by mouth once daily for the duration of lu-
teal support. Embryo transfer occurred on day 3 or day
5 after insemination or intracytoplasmic sperm injection.
Assessments
Patients completed a survey to assess administration prefer-
ences of PVI and PIO at the start of their luteal phase
support and at their final visit. Questions included on the
PVI and PIO patient surveys are shown in the Assessmentssubsection under Methods. Responses to the survey assessed
convenience and ease of use and other variables such as
pain and discomfort associated with study drug
administration. Assessment of safety and tolerability in-
cluded documentation of AEs and serious AEs, results
from clinical laboratory evaluations and electrocardiograms,
measurements of vital signs, and findings from TVU.
Patient survey assessing administration preferences of
progesterone vaginal insert (PVI) and progesterone in oil
(PIO)
Section 1*† (PVI and PIO)
For the following questions, please choose the response
which best reflects your experience.
1. How would you describe the convenience of




● Neither convenient or inconvenient
● Somewhat inconvenient
● Very inconvenient
2. How would you describe the ease of administering/
dosing [Endometrin/progesterone in oil injections]?
● Very easy
● Somewhat easy
● Neither easy or difficult
● Somewhat difficult
● Very difficult
3. In a previous ART cycle, were you prescribed
progesterone supplementation?
● Yes
● No (Skip questions 4, 5).
4. If you answered ‘Yes’ to question 3: Which of the
following progesterones were you prescribed in a
previous cycle?




● Pharmacy compounded suppositories
● Endometrin
5. If you answered ‘Yes’ to question 3: Overall, how
would you compare [Endometrin/ progesterone in
oil injections] to the different progesterone used in a
previous cycle?
● Very convenient and easy to use
● Somewhat convenient and easy to use
● Neither convenient or inconvenient and easy to use
● Very inconvenient and difficult to use
6. Please rate your overall satisfaction level with
[Endometrin/ progesterone in oil injections]
● Very satisfied
Table 1 Patient demographics and baseline characteristics,
ITT population
Parameter PVI PIO
(n = 53) (n = 57)
Age, y 30.9 (20–40) 31.5 (22–41)
BMI, kg/m2 26.9 (5.2) 28.9 (6.5)
Race
White 38 (71.7) 43 (75.4)
Black 0 1 (1.8)
Asian 9 (17.0) 2 (3.5)
Hispanic 6 (11.3) 10 (17.5)
Other 0 1 (1.8)
Duration of infertility, months 32.2 (19.7) 49.6 (44.6)
26.0 (10–96) 34.0 (12–240)
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● Neither satisfied nor dissatisfied
● Somewhat dissatisfied
● Very dissatisfied
7. If given a choice, which progesterone would you
prefer to use?




● Pharmacy compounded suppositories
● Endometrin
Section 2¶ (PIO only)
1. How painful were the progesterone in oil injections?
ART History
Number previous IVF cycles 0.2 (0.5) 0.2 (0.4)
Number failed IVF cycles 0.1 (0.3) 0.1 (0.3)
Number previous ovulation
induction cycles*
4.2 (3.1) 5.3 (6.8)
Number failed ovulation
induction cycles†
4.1 (3.1) 5.2 (6.8)
Gonadotropin for ovulation induction
rFSH 28 (52.8) 30 (52.6)
HP-hMG 25 (47.2) 27 (47.4)
Values are n (%), median (range), or means (standard deviation).
*Excluding IVF, gamete intrafallopian transfer, and/or pronuclear stage
embryo transfer.
†Excluding IVF.
ITT, intent to treat; PVI, progesterone vaginal insert; PIO, progesterone in oil;
BMI, body mass index; ART, assisted reproductive technologies; rFSH,
recombinant follicle-stimulating hormone; HP-hMG, highly purified human
menopausal gonadotropin.● Very painful
● Somewhat painful
● Neither painful nor painless
● Somewhat painless
● Very painless
2. How would you describe your partner’s level of
anxiety in giving the progesterone in oil injections?.
● Very anxious
● Somewhat anxious
● Neither anxious nor comfortable
● Not anxious
3. Did the progesterone in oil injections make you
consider dropping out of treatment?
● Yes
● No
* Separate surveys were administered for PVI and PIO.
† “Endometrin” or “progesterone in oil injection” was
included in the questions on each survey, and referred
to PVI or PIO, respectively.
‡ Sections 1 and 2 on PVI survey.
¶ Section 2 PIO survey.
Statistical analysis
Fisher’s exact test was used to determine treatment group
comparisons for categorical variables. As appropriate,
one-way analysis of variance or the Wilcoxon rank sum
test were used, to determine treatment group comparisons
for continuous variables. Statistical significance was de-
clared if the two-sided P value was ≤ 0.05. Statistical
analyses were performed using statistical software (SAS
version 9.2; SAS Institute Inc, Cary, NC, USA).
Results
Demographic characteristics were similar for the PVI
and PIO treatment groups (Table 1). The majority of
women enrolled in the study were Caucasian, with
71.7% and 75.4% in the PVI and PIO groups,respectively. Mean age was 30.9 and 31.5 years in the
PVI and PIO groups, respectively.
The number of women who received PVI or PIO for
luteal phase support, underwent embryo transfer, and
completed 10 weeks of luteal phase support are shown
in Table 2. A negative result on serum pregnancy test
was the most frequent reason for discontinuing luteal
phase support in both groups (PVI, 26%; PIO, 21%). PVI
was administered twice daily in 23.1% and 3 times daily
in 76.9% of women randomized to PVI.
Patient-reported outcomes
The convenience/ease of administration and overall pa-
tient satisfaction for PVI or PIO based on survey respon-
ses at the final study visit are shown in Figure 1. More
women commented on the convenience and ease of ad-
ministration of PVI than IM PIO. Conversely, a majority
of patients and their partners described pain and anxiety,
respectively, associated with PIO. Progesterone treatment
was reported as “very” or “somewhat convenient” to
Table 2 Disposition of women randomized to luteal
support with progesterone vaginal insert and
progesterone in oil
Parameter PVI PIO
(n = 53) (n = 57)
Received luteal phase support 48 (90.6) 50 (87.7)
Underwent embryo transfer 46 (86.8) 49 (86.0)
Biochemical pregnancy* 32 (60.4) 37 (64.9)
Clinical pregnancy† 27 (50.9) 29 (50.9)
Ongoing pregnancy‡ 25 (47.2) 28 (49.1)
Values are n (%).
*Positive result on serum β-hCG test 12–14 days after embryo transfer, P = 0.853.
†Gestational sac visualized using transvaginal ultrasonography approximately
4 weeks after embryo transfer, P = 1.0.
‡Fetal heart movements identified using transvaginal ultrasonography at
approximately 6 weeks’ gestation, P = 0.851.
PVI, progesterone vaginal insert; PIO, progesterone in oil; β-hCG, beta human
chorionic gonadotropin.
Figure 1 Convenience, ease, and overall patient satisfaction of
administering/dosing progesterone vaginal insert (PVI) and
progesterone in oil (PIO).
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40.9% in the PIO group (Figure 1A). The “ease of use” of
progesterone treatment was considered “very” or “some-
what easy” to administer by 97.4% in the PVI group com-
pared with only 56.8% in the PIO group (Figure 1B). In
the PIO group, 65.9% found treatment “very” or “some-
what painful”. Overall satisfaction with progesterone treat-
ment was higher for PVI compared to PIO (71.8% of
women were “very satisfied” with PVI compared with only
18.2% of women who received PIO) (Figure 1C).
In the study, 24% (11/46) and 31% (15/49) of patients
in the PVI and IM PIO arms, respectively, had used pro-
gesterone in a previous treatment cycle. Of these, 90.9%
in the PVI group found vaginal inserts “very” or “some-
what easier” to use than a previous progesterone treat-
ment. For those women in the PIO group, only 33.3%
found this treatment “very” or “somewhat easier” to use
than any previous progesterone treatment. In addition,
47.7% of patients’ partners in the PIO group reported
being “very” or “somewhat anxious” about administering
the treatment. No women in the PVI group found the
vaginal inserts “difficult to administer” or expressed “dis-
satisfaction with administration” of the insert (Figure 1B
and C). Overall, more patients expressed a preference
for PVI than IM PIO.
Pregnancy rates
There were no significant differences in the biochemical,
clinical, and ongoing pregnancy rates for those patients
in the PVI group compared with those rates for patients
in the PIO group (see Table 2). Biochemical pregnancy
rates were 60.4% and 64.9% for the PVI and PIO groups,
respectively (P = 0.853). Clinical pregnancies occurred in
50.9% in both the PVI and PIO groups (P = 1.0). The on-
going pregnancy rates were 47.2% and 49.1% for the PVI
and PIO groups, respectively (P = 0.851).Adverse events
One or more AEs were reported during progesterone
treatment by 30.2% in the PVI group and 31.6% in the
PIO group. Most AEs were of mild or moderate intensity
in both groups. Abdominal distension, lower abdominal
pain, nausea, and ovarian hyperstimulation syndrome
(OHSS) were the most common AEs reported in both
groups.Discussion
The IM and vaginal routes of administration are used
almost exclusively in clinical practice when progesterone
is given to patients for luteal phase support during
ART [4,6]. Reports indicate that the vaginal and IM
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pregnancy outcomes [6,13,15].
Moreover, this analysis provides a comprehensive, pro-
spective comparison of patient-reported convenience
and ease of use, overall patient satisfaction, and toler-
ability for PVI compared to IM PIO from a population
of women undergoing cycles of IVF. The most distin-
guishing difference between PVI and PIO in this study
was the overall patient preference for PVI. Despite the
need to administer PVI either twice a day or 3 times a
day, 82.6% of the patients in the PVI group found it
“very” or “somewhat convenient” compared with 44.9%
of women in the PIO group. Furthermore, 90% of those
in the PVI group found this treatment to be “very” or
“somewhat easier” to use than a previous progesterone
treatment. This is in contrast to patient response in the
PIO group, where 33.3% found PIO “very” or “somewhat
easier” to use than a previous progesterone treatment.
Only a few studies with progesterone for luteal phase
support during cycles of IVF have attempted to assess
patient treatment satisfaction and ease of use. In two
previous studies comparing administration of proges-
terone vaginal gel to IM PIO, patients reported better
satisfaction with vaginal gel when compared to IM PIO
[15,18]. In a study by Schoolcraft et al., patients found
the vaginal gel easier to use, less painful, and less time
consuming to administer when compared to treatment
with IM PIO during a previous cycle of IVF [19]. Data
on patient satisfaction were obtained prospectively in
these studies; however, the data collected were more
limited in scope than the data collected in the current
study. Results from this survey of patient satisfaction,
convenience, ease of use, and tolerability provide a more
comprehensive assessment of patient-reported satisfac-
tion than analysis included in previous studies.
No significant difference in biochemical, clinical, or
ongoing pregnancy rates were observed among the treat-
ment groups. Pregnancy outcomes in this study were
similar to those reported in previous studies comparing
vaginal to IM administration of progesterone for luteal
support in women of a similar age range [6-11,14,15].
Progesterone administered vaginally for luteal phase
support has been shown to be well tolerated. The most
common treatment-emergent AEs associated with PVI
include nausea, abdominal pain, OHSS, and oocyte re-
trieval pain [22]. Breast tenderness, headache, abdominal
pain, abdominal distension, nonspecific muscle spasms,
and vaginal discharge have been associated with vaginal
gel [23].
It can be difficult to clearly elucidate the true cause-
effect relationship of AEs reported during a clinical
study. Nausea, OHSS, abdominal distention, and abdo-
minal pain reported most frequently during this study
by both PVI and PIO users were also commonlyreported AEs when medications given for ovarian stimu-
lation and IVF were used [21,22,24,25]. Injection site ir-
ritation and redness have been reported frequently with
administration of IM PIO [18,26].
The results of this comprehensive, prospective patient
survey and other similar reports suggest that PVI pro-
vides an easy-to-use and convenient method for pro-
viding the necessary luteal phase support for IVF cycles
without the pain and inconvenience of daily IM injec-
tions and with comparable pregnancy rates.
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